Identification of Type 1 and Type 2 α-Synuclein-Seeds by CSF Seed Amplification Assay in Patients With Movement Disorders

BACKGROUND AND OBJECTIVES: A novel α-synuclein (syn) seed amplification assay (synSAA) differentiates 2 types of syn-seeds in CSF: type1, associated with Lewy bodies (LBs), and type2, associated with glial-cytoplasmic inclusions, the hallmark of multiple system atrophy (MSA). However, syn-copathology extends beyond synucleinopathies, and copathologies are increasingly relevant. Different syn-seeds have been assessed in highly characterized research cohorts, but data assessing type and frequency in patients from routine clinical encounters are lacking. Hence, our objective was to determine frequency, type, and clinical association of different syn-seeds in CSF in a large cohort from a movement disorders (MDs) clinic. METHODS: This cross-sectional study included consecutive patients from a MD clinic between 2009 and 2025. CSF was tested with synSAA and clinical data derived from medical records. RESULTS: We recruited 1,059 patients (mean age 70.5 ± 10.5 years; 38.4% female; mean disease duration 4.0 ± 4.6 years). Syn-seeds were detected in 54.2% of patients, with type1-seeds predominating (88.5%). High synSAA positivity was observed in Parkinson disease (PD) (84.7%), dementia with LB (93.4%), MSA (84.5%), isolated REM-sleep behavior disorder (iRBD) (80.0%), and normal pressure hydrocephalus (NPH) with PD (87.0%). Undetermined hypokinetic MD showed 53.7% positivity. Moderate proportions (∼25-33%) were detected in Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal syndrome, and idiopathic NPH without PD, while other neurologic disorders showed 20.9% positivity. Type2-seeds were the major seed type in MSA (79.6% of syn-seeds) and minor type in PD (6.2%), PSP (9.1%), and undetermined hypokinetic MD (13.8%). Overall, type2-seeds were present in only 2.6% of non-MSA patients. Patients with type1-seeds had worse olfaction and more hallucinations. Multivariable regression identified impaired olfaction (OR = 0.67 per point increase of identified smells out of 12, higher scores indicating better olfaction) significantly associated with type1-seeds. DISCUSSION: Our results provide reference data on syn-seed frequency in routine clinical patients, demonstrating that type1-seeds indicate common underlying syn-pathology or copathology associated with hyposmia and hallucinations. Type2-seeds are specific to MSA and detection of type2-seeds outside the clinical MSA spectrum can improve diagnosis of patients with atypical presentations because our results match neuropathologic MSA studies. In vivo identification of different seed types will improve diagnosis, clinical trial stratification, and development of targeted therapies.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-11-16
DOI
https://doi.org/10.1212/wnl.0000000000218763
Citations
1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
2.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identification of Type 1 and Type 2 α-Synuclein-Seeds by CSF Seed Amplification Assay in Patients With Movement Disorders

Sandrina Weber, Claudia Trenkwalder, Jens Ebentheuer, Luis Concha‐Marambio et al.
1 citations
Neurology
Parkinson's Disease Mechanisms and Treatments
2.67
article

Identification of Type 1 and Type 2 α-Synuclein-Seeds by CSF Seed Amplification Assay in Patients With Movement Disorders

Sandrina Weber, Claudia Trenkwalder, Jens Ebentheuer, Luis Concha‐Marambio, Yihua Ma, Susana Schnell, Maritta Starke, Carly M. Farris, Brit Mollenhauer, Michael Bartl, Jesusa E. Kalinkara-Gomez, Holger Aust
article en
1 citations

Abstract

BACKGROUND AND OBJECTIVES: A novel α-synuclein (syn) seed amplification assay (synSAA) differentiates 2 types of syn-seeds in CSF: type1, associated with Lewy bodies (LBs), and type2, associated with glial-cytoplasmic inclusions, the hallmark of multiple system atrophy (MSA). However, syn-copathology extends beyond synucleinopathies, and copathologies are increasingly relevant. Different syn-seeds have been assessed in highly characterized research cohorts, but data assessing type and frequency in patients from routine clinical encounters are lacking. Hence, our objective was to determine frequency, type, and clinical association of different syn-seeds in CSF in a large cohort from a movement disorders (MDs) clinic. METHODS: This cross-sectional study included consecutive patients from a MD clinic between 2009 and 2025. CSF was tested with synSAA and clinical data derived from medical records. RESULTS: We recruited 1,059 patients (mean age 70.5 ± 10.5 years; 38.4% female; mean disease duration 4.0 ± 4.6 years). Syn-seeds were detected in 54.2% of patients, with type1-seeds predominating (88.5%). High synSAA positivity was observed in Parkinson disease (PD) (84.7%), dementia with LB (93.4%), MSA (84.5%), isolated REM-sleep behavior disorder (iRBD) (80.0%), and normal pressure hydrocephalus (NPH) with PD (87.0%). Undetermined hypokinetic MD showed 53.7% positivity. Moderate proportions (∼25-33%) were detected in Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal syndrome, and idiopathic NPH without PD, while other neurologic disorders showed 20.9% positivity. Type2-seeds were the major seed type in MSA (79.6% of syn-seeds) and minor type in PD (6.2%), PSP (9.1%), and undetermined hypokinetic MD (13.8%). Overall, type2-seeds were present in only 2.6% of non-MSA patients. Patients with type1-seeds had worse olfaction and more hallucinations. Multivariable regression identified impaired olfaction (OR = 0.67 per point increase of identified smells out of 12, higher scores indicating better olfaction) significantly associated with type1-seeds. DISCUSSION: Our results provide reference data on syn-seed frequency in routine clinical patients, demonstrating that type1-seeds indicate common underlying syn-pathology or copathology associated with hyposmia and hallucinations. Type2-seeds are specific to MSA and detection of type2-seeds outside the clinical MSA spectrum can improve diagnosis of patients with atypical presentations because our results match neuropathologic MSA studies. In vivo identification of different seed types will improve diagnosis, clinical trial stratification, and development of targeted therapies.

NeurologyVol. 107(11)
Amprion (United States) (US), Universitätsmedizin Göttingen (DE), Paracelsus Elena Klinik Kassel (DE)
Good health and well-being
Openalex Percentile: Top 17%
Parkinson's Disease Mechanisms and Treatments
2.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon